Alopecia Market

Market Definition:

The Alopecia Market size was valued at USD 8.12 billion in 2021 and is expected to reach USD 16.09 billion by 2030, with a CAGR of 7.9% from 2022 to 2030. Alopecia, also known as chloasma, is a term used to describe excessive hair damage under certain medical conditions or dietary issues. It is an autoimmune disorder in which the immune system of the body attacks the healthy hair follicles, leading to partial or complete hair loss.

In extreme cases, it can also result in loss of entire body hair. In most of the cases, this condition grips people before they reach the age of 30. Unhealthy diets and sedentary lifestyles are some of the causes that lead to the loss of hair. Moreover, aging, hormonal imbalance, and depression, especially among the middle-aged population, can also lead to hair loss.

Market Dynamics and Trends:

Rise in the prevalence of chronic diseases such as cancer, polycystic ovary syndrome (PCOS), and arthritis along with rise in stress level, increase in geriatric population, hormonal imbalance, and unhealthy diets are expected to support the growth of the global alopecia market.

Moreover, increase in cancer treatment that leads to hair loss from patient body and rise in water and air pollution that harms the health of the hair and causes baldness & early breakage are expected to further propel the growth of the market during the forecast period.

However, high cost and unsuccessful results of this treatment coupled with side effects such as scalp irritation and unwanted hair growth are some of the factors restraining the growth of market. On the contrary, rise in adoption of alopecia treatment products along with increase in patient awareness regarding the therapy due to broadcasting and displaying of products on social media platforms are expected to create ample opportunities for market players in the coming years.

Market Segmentations and Scope of the Study:

The global alopecia market is segmented on the basis of disease type, treatment, sales channel, end use, gender, and geography. On the basis of disease type, the market is categorized into androgenetic alopecia, alopecia areata, traction alopecia, cicatricial alopecia, alopecia totalis, and alopecia universalis. On the basis of treatment the market is segment into pharmaceutical and devices. On the basis of sales channel, the market is segmented into prescriptions and OTC. On the basis of end use the market is homecare settings and dermatology segments. On the basis of gender, the market is bifurcated into female and male. Geographic breakdown and analysis of each of the aforesaid segments includes regions such as North America, Europe, Asia-Pacific, and RoW.

Geographical Analysis:

North America holds the dominant share in the global alopecia market at present and is expected to continue its dominance during the forecast period. This is attributed to factors such as established healthcare infrastructure, rise in number of hospitals equipped with advanced medical facilities, rise in healthcare reforms, and technological advancements in medical science.

In addition, increasing number of research activities in the field of drugs or medicine, rising demand for the-counter dietary supplements, and increasing popularity and affordability of over the counter (OTC) medications along with dietary supplements drive the market growth.

Moreover, rising popularity of cosmetic procedures due to surging focus on improving aesthetic appearance is boosting patients' interest in new and emerging treatment modalities of alopecia. This factor is expected to further drive the market in this region.

Moreover, Asia-Pacific is expected to witness a steady rise in the market, owing to advancements in clinical evaluation and management, increasing number of research grants and funding available to accelerate alopecia research and development, and rising prevalence of various genetic disorders. Also, malnutrition & unhealthy lifestyle attributed to poverty and growing population in the region drives the market growth.

In addition, rising number of R&D activities have increased knowledge and understanding of the molecular mechanism of androgenetic alopecia and alopecia areata. This has raised possibilities for the development of new treatments. Moreover, growing demand of novel therapeutic approaches such as Platelet-rich plasma therapy, fecal transplants, and cytokine-targeted therapy are expected to drive the growth of the alopecia market in this region.

Competitive Landscape:

Various market players operating in the global alopecia market include Capillus, LLC, Daiichi Sankyo Company, Cipla, Inc., Transitions Hair, Johnson & Johnson, GlaxoSmithKline Plc, Sun Pharmaceutical Industries Ltd., Merck & Co., Inc., and Vita biotics Ltd. These market players are adopting product launches to maintain their dominance in the alopecia market.

For instance, in June 2020, Capillus launched CAPILLUS272, which is a mobile battery-powered laser product. It is worn under a hat for 30 minutes every day and is easy to use for patients and eliminates the continual office visits for treatment. Also, in January 2020, Transitions hair of Indiana launched new treatment for thinning hair and hair loss. It is a fast and pain free treatment that requires only 45 minutes for the completion of the entire treatment of hair loss.

Key Benefits:

• The alopecia market report provides the quantitative analysis of the current market and estimations from 2022 to 2030. This analysis assists in identifying the prevailing market opportunities to capitalize on.

• The study comprises of a deep dive analysis of the alopecia market trends including the current and future trends for depicting the prevalent investment pockets in the market.

• The information related to key drivers, restraints and opportunities and their impact on the alopecia market is provided in the report.

• The competitive analysis of the market players along with their market share in the alopecia market is mentioned.

• The SWOT analysis and Porter’s Five Forces model are elaborated in the study.

• The value chain analysis in the market study provides a clear picture of the stakeholders’ roles.

Key Market Segments:

By Disease Type

• Androgenetic Alopecia

• Alopecia Areata

• Traction Alopecia

• Cicatricial Alopecia

• Alopecia Totalis

• Alopecia Universalis

By Treatment

• Pharmaceutical

• Devices

By Sales Channel

• Prescriptions

• OTC

By End Use

• Homecare Settings

• Dermatology Segments

By Gender

• Female

• Male

By Geography

• North America

  • The U.S.

  • Canada

  • Mexico

• Europe

  • U.K.

  • Germany

  • France

  • Italy

  • Spain

  • Rest of Europe

• Asia-Pacific

  • China

  • India

  • Japan

  • South Korea

  • Australia

  • Rest of Asia-Pacific

• RoW

  • UAE

  • Saudi Arabia

  • South Africa

  • Brazil

  • Remaining countries

KEY PLAYERS

• Capillus, LLC

• Cipla, Inc.

• Daiichi Sankyo Company

• GlaxoSmithKline Plc

• Johnson & Johnson

• Merck & Co., Inc.

• Sun Pharmaceutical Industries Ltd.

• Transitions Hair

• Vitabiotics Ltd.

REPORT SCOPE AND SEGMENTATION:

Parameters	Details
Analysis Period	2021–2030
Base Year Considered	2021
Forecast Period	2022–2030
Market Size Estimation	Billion (USD)
Market Segmentation	By Disease Type (Androgenetic Alopecia, Alopecia Areata, Traction Alopecia, Cicatricial Alopecia, Alopecia Totalis, and Alopecia Universalis), by Treatment (Pharmaceutical and Devices), by Sales Channel (Prescriptions and OTC), by End-use (Homecare Settings and Dermatology Segments) and by Gender (Female and Male)
Geographical Segmentation	North America (U.S., Canada, Mexico) Europe (U.K., Germany, France, Italy, Spain, Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Australia, Rest of Asia-Pacific), Rest of the World (UAE, Saudi Arabia, South Africa, Brazil, Remaining countries)
Companies Profiled	Capillus, LLC, Daiichi Sankyo Company, Cipla, Inc., Transitions Hair, Johnson & Johnson, GlaxoSmithKline Plc, Sun Pharmaceutical Industries Ltd., Merck & Co., Inc., and Vita biotics Ltd.